Scientific Program

Monday, 27 November




 Congress Opening


 Session I: Opening and Keynote Presentations
 Lessons from High Impact Clinical Trials in 2017
 Ralph DeFronzo, USA
 Innovation in Diabetes – What’s Ahead

 Changing Management Guidelines: Good  Evidence and Bad Evidence
 Philip Home, UK



 Networking Break and visit the Exhibition


 Session II: Current Regulatory Trends in Diabetes and Drug Development

 EMA Perspective
 Giuseppe Rosano, UK

 US and FDA Perspective 
 Zan Fleming, USA

 How to Pick and Qualify a CRO
 James Nolan, Inclinica, USA

 Asia/China Perspective
 Guang Ning, China



 Lunch Break, Networking and visit the Exhibition


 Session III: Design a Clinical Program for Success
 Convincing Authorities for Innovative Endpoints 
 Zan Fleming, USA

 How New Technologies may Help in Designing Trials in Diabetes
 Paolo Pozzilli, Italy

 The Role of DSMB (IDMC)
 Philip Home, UK

 Clinical Trials in Emerging Nations
 Guang Ning, China

 Assessing and Measuring Hypoglycemia 
 Avivit Cahn, Israel

 Clinical Trials in Older Patients with Frailty Syndrome a Need for Evidence Based  Studies
 Markolf Hanefeld, Germany


 Networking Break and visit the Exhibition


 Session IV: Free Oral Communications

   Oral Presentations from Selected Abstracts


 Networking Reception in the Exhibition Area

Tuesday, 28 November




 Session V: Phase 2/3 Studies
 Why are Phase 2 Studies so Often Misleading?
 Andreas Pfützner, Germany

 A Critical Look at Inclusion/Exclusion Criteria- A1C Targets and Patient  Populations 

 Diabetic Neuropathy and / or  Tools to Quantify Vascular Effects in Phase Studies  and / or Biomarkers in Diabetes Studies
 Thomas Forst, Profil, Germany

 Public Perception of Clinical Trials for Diabetes
 Helen Gao, Close Concerns, USA

  Can Real World Evidence Substitute for RCTs to Gain Approval for New Drugs?
  Eberhard Standl, Germany



Coffee Break, Exhibition and  Guided Poster Walks and visit the Exhibition


 Session VI: Cardiovascular Outcome Studies Part 1: What can we Learn from    Retrospective Data
 Merits of Observational versus Randomized Clinical Trial Data
 John Lachin, U.S.A

 Big Data: Advantages and Shortfalls
 Ran Goshen, Israel



Lunch Break, Networking and visit the Exhibition


 Session VII: Cardiovascular Outcome Studies Part 2: Design, Interpretation and Translation
 Next Generation of Diabetes Trials (Round Table)
 Neda  Rasouli, USA, Ralph DeFronzo, USA, Zan Fleming, USA

 Considerations in the Selection and Analysis of Multiple Outcomes
 John Lachin, USA

 Algorithm Dilemma for the Management of Diabetes.
 Antonio Ceriello, Spain

 Clinical Trials in Diabetic Kidney Disease: The Need for a Personalized Approach 
 Hiddo J. Lambers Heerspink, Netherlands 
 Interpretation and Translation of Cardiovascular studies in clinical  practice
 Neda  Rasouli, USA

 CVOTs 2017 - what have we learned?
 Oliver Schnell,  Germany


 Networking Break and visit the Exhibition


 Session VIII: Special National Program to Enhance Drug Development
 Special National Program to Enhance Drug Development 

  The Importance of IP and How to Select the Right Lawyer and Firm
  James Nolan, InClinica, USA
 Panel Discussion


 Congress Closing